EARLY Labs Business
Product stage
Clinical Trial
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Target Customer
Healthcare & Life SciencesHealthcareProvidersPatients
Core Technology
Artificial IntelligenceMachine LearningBiologicalsMoleculesSensingScent
Tags (12)
early-detectioncancer-diagnosticsmedical-technologiesscreeningbiomarkerscancer-researchdiagnosticscancerpulmonarymachine-learningbiosensorsbiotechnology
EARLY Labs Financials
Undisclosed
Capital raised
Cumulative Funding Raised Over Time ($)
EARLY Labs Lifecycle
Cumulative Funding Raised Over Time
EARLY Labs News
4 articles
Scientists plan UK clinical trial of rats trained to sniff out cancer
Israeli scientists have trained rats to sniff out lung cancer from human urine with 90% accuracy. The company behind the testing, Early Labs, plans to set up clinical trials in the UK to detect other forms of cancer using urine samples. The rats were able to correctly identify lung cancer samples 93% of the time. The technique is also being tested on colon cancer samples. Early diagnosis of cancer is crucial for successful treatment, and certain cancers can trigger specific body odors that can be found in bodily fluids. The urine test for cancer detection could be a game-changer in early cancer diagnosis.
Customers
Israeli scientists training rats to sniff out lung cancer now want UK trial
Israeli firm Early Labs has trained rats to detect lung cancer from human urine with a 93% accuracy rate. The company, which has spent two years training the rats, now plans to conduct clinical trials in the UK. The test can be taken at home, with the sample then sent to a lab via GP surgeries or pharmacies. The firms chief operating officer, Avichay Porat, described the technique as a real game-changer and revealed it is also being tested on colon cancer samples.
Expand
Lab claims it teaches rats to detect lung cancer with 93% accuracy by sniffing urine
Israeli startup Early has developed a system to train rats to detect cancer with 93% accuracy by smell-testing urine samples. The company, which raised $6.2 million in investment, aims to use the rats to process samples provided by individuals from their own homes. The rats are trained to identify lung cancer by smelling the urine samples. If successful, the technology could eliminate the need for waiting for screening and provide easy access to early diagnosis. The rats are as accurate as low dose CT scans currently used for lung cancer screening. The training system lasts for four months and takes advantage of rats highly developed sense of smell and intelligence.
InvestmentCustomers
N12 - פיתוח ישראלי: חולדות יוכלו לזהות סרטן ריאות בשלב מוקדם
Israeli company EARLY has developed a revolutionary system that can detect lung cancer at an early stage using the sense of smell of dogs. The system has a success rate of 93% in identifying lung cancer in its early stages. The company aims to make cancer a chronic disease that can be lived with. The technology is currently undergoing FDA approval. The hope is that in the near future, cancer tests will be simple, fast, and affordable for all types of cancer.
Customers
EARLY Labs Team
Michal Mark Danieli
Founder & CEO
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
